Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer

Fallon E. Chipidza; Mohammed Alshalalfa; Brandon A. Mahal; R. Jeffrey Karnes; Yang Liu; Elai Davicioni; Neil E. Martin; Kent W. Mouw; Felix Y. Feng; Paul L. Nguyen; Vinayak Muralidhar

doi:10.1016/j.clgc.2020.08.004

Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer

Fallon E. Chipidza, Mohammed Alshalalfa, Brandon A. Mahal, R. Jeffrey Karnes, Yang Liu, Elai Davicioni, Neil E. Martin, Kent W. Mouw, Felix Y. Feng, Paul L. Nguyen, Vinayak Muralidhar

Urology

Research output: Contribution to journal › Article › peer-review

Abstract

TP53 is the most frequently mutated gene in cancer. We developed a molecular signature detecting underlying TP53 alterations. This signature identified aggressive tumors, and after adjusting for known predictors of worse outcomes, the signature identified patients with prostate cancer likely to develop metastases. These findings may help doctors identify patients with prostate cancer with aggressive tumors and hence, choose the optimal treatment.

Original language	English (US)
Journal	Clinical Genitourinary Cancer
DOIs	https://doi.org/10.1016/j.clgc.2020.08.004
State	Accepted/In press - 2020

Keywords

Biologic signature
Genomic classifier
Risk stratification
TCGA prostate
TP53 gene

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.clgc.2020.08.004

Fingerprint Dive into the research topics of 'Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer'. Together they form a unique fingerprint.

Cite this

Chipidza, F. E., Alshalalfa, M., Mahal, B. A., Karnes, R. J., Liu, Y., Davicioni, E., Martin, N. E., Mouw, K. W., Feng, F. Y., Nguyen, P. L., & Muralidhar, V. (Accepted/In press). Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2020.08.004

Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. / Chipidza, Fallon E.; Alshalalfa, Mohammed; Mahal, Brandon A.; Karnes, R. Jeffrey; Liu, Yang; Davicioni, Elai; Martin, Neil E.; Mouw, Kent W.; Feng, Felix Y.; Nguyen, Paul L.; Muralidhar, Vinayak.

In: Clinical Genitourinary Cancer, 2020.

Research output: Contribution to journal › Article › peer-review

Chipidza, Fallon E. ; Alshalalfa, Mohammed ; Mahal, Brandon A. ; Karnes, R. Jeffrey ; Liu, Yang ; Davicioni, Elai ; Martin, Neil E. ; Mouw, Kent W. ; Feng, Felix Y. ; Nguyen, Paul L. ; Muralidhar, Vinayak. / Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. In: Clinical Genitourinary Cancer. 2020.

@article{0b0a316f66014a1aa5735686cd437926,

title = "Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer",

abstract = "TP53 is the most frequently mutated gene in cancer. We developed a molecular signature detecting underlying TP53 alterations. This signature identified aggressive tumors, and after adjusting for known predictors of worse outcomes, the signature identified patients with prostate cancer likely to develop metastases. These findings may help doctors identify patients with prostate cancer with aggressive tumors and hence, choose the optimal treatment.",

keywords = "Biologic signature, Genomic classifier, Risk stratification, TCGA prostate, TP53 gene",

author = "Chipidza, {Fallon E.} and Mohammed Alshalalfa and Mahal, {Brandon A.} and Karnes, {R. Jeffrey} and Yang Liu and Elai Davicioni and Martin, {Neil E.} and Mouw, {Kent W.} and Feng, {Felix Y.} and Nguyen, {Paul L.} and Vinayak Muralidhar",

year = "2020",

doi = "10.1016/j.clgc.2020.08.004",

language = "English (US)",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

}

TY - JOUR

T1 - Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer

AU - Chipidza, Fallon E.

AU - Alshalalfa, Mohammed

AU - Mahal, Brandon A.

AU - Karnes, R. Jeffrey

AU - Liu, Yang

AU - Davicioni, Elai

AU - Martin, Neil E.

AU - Mouw, Kent W.

AU - Feng, Felix Y.

AU - Nguyen, Paul L.

AU - Muralidhar, Vinayak

PY - 2020

Y1 - 2020

N2 - TP53 is the most frequently mutated gene in cancer. We developed a molecular signature detecting underlying TP53 alterations. This signature identified aggressive tumors, and after adjusting for known predictors of worse outcomes, the signature identified patients with prostate cancer likely to develop metastases. These findings may help doctors identify patients with prostate cancer with aggressive tumors and hence, choose the optimal treatment.

AB - TP53 is the most frequently mutated gene in cancer. We developed a molecular signature detecting underlying TP53 alterations. This signature identified aggressive tumors, and after adjusting for known predictors of worse outcomes, the signature identified patients with prostate cancer likely to develop metastases. These findings may help doctors identify patients with prostate cancer with aggressive tumors and hence, choose the optimal treatment.

KW - Biologic signature

KW - Genomic classifier

KW - Risk stratification

KW - TCGA prostate

KW - TP53 gene

UR - http://www.scopus.com/inward/record.url?scp=85090489643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090489643&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.08.004

DO - 10.1016/j.clgc.2020.08.004

M3 - Article

AN - SCOPUS:85090489643

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

ER -